Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 23;72(6):1835–1851. doi: 10.1007/s00262-022-03364-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — SPI1 is upregulated in high-dose irradiation-exposed TAMs and activates SIGLEC9 transcription. a, expression of transcription factors in different types of immune cells in HNSC analyzed by single-cell analysis; b, expression of CEBPA and SPI1 in esophagus analyzed by single-cell analysis; c, SPI1 predicted as a candidate upstream regulator of SIGLEC9; d-e, mRNA and protein expression of SPI1 in high-dose irradiation-exposed TAMs analyzed by qPCR (d) and WB (e) analyses; f, SPI1 and SIGLEC9 mRNA in TAMs pre-transfected with sh-SPI1 analyzed by qPCR analysis; g, putative binding site of SPI1 to SIGLEC9 promoter; h, binding of SIGLEC9 promoter with SPI1 in TAMs upon high-dose irradiation treatment and sh-SPI1 transfection analyzed by ChIP-qPCR assay; i, transcription activity of SIGLEC9 promoter in TAMs upon high-dose irradiation treatment and sh-SPI1 transfection analyzed by luciferase assay. Differences of the normally distributed data between groups were analyzed by two-way ANOVA (d, e, f, h and i). Significance of difference was analyzed by Sidak's multiple comparisons test (d and e), Dunnett's multiple comparisons test (f) and Tukey's multiple comparisons test (h and i). ***p < 0.001, ****p < 0.0001